• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

       

      A GENERALLY WELL TOLERATED TREATMENT REGIMEN1,6

      Data pooled from SURVEYOR 1 and 2, EXPEDITION 1, MAGELLAN 1, and ENDURANCE 1, 2, 3 and 4 studies.6

       

      Please see full Prescribing Information
      For comprehensive safety information, please refer to the Maviret
      Summary of Product Characteristics

      *Cure = sustained virologic response (SVR12), defined as HCV RNA less than lower limit of quantification at 12 weeks after the end of treatment and was the primary endpoint in all the studies.1


      I want to receive more information via a product specialist 

      Explore supporting materials related to Maviret


      References

      1. Maviret Summary of Product Characteristics. AbbVie Ltd. Available at: www.medicines.org.uk
      2. Harvoni Summary of Product Characteristics. Gilead Sciences Ltd. Available at: www.medicines.org.uk (accessed December 2020).
      3. Epclusa Summary of Product Characteristics. Gilead Sciences Ltd. Available at: www.medicines.org.uk (accessed December 2020).
      4. Vosevi Summary of Product Characteristics. Gilead Sciences Ltd. Available at: www.medicines.org.uk (accessed December 2020).
      5. Zepatier Summary of Product Characteristics. Merck Sharp & Dohme Ltd. Available at: www.medicines.org.uk (accessed December 2020).
      6. Dufour J-F et al. [Poster FRI-238]. Presented at the European Association for the Study of the Liver. April 19−23, 2017. Amsterdam, The Netherlands.
       

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk .
      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      UK-MAVI-200067. Date of preparation: December 2020